The information contained
within this announcement is deemed to constitute inside information
as stipulated under the Market Abuse Regulation (EU) No. 596/2014,
as incorporated into UK law by the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement,
this inside information is now considered to be in the public
domain.
18 December 2024
CRISM Therapeutics
Corporation
("CRISM",
"CRISM Therapeutics" or the "Company")
European Patent
Grant
CRISM Therapeutics Corporation (AIM:
CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs,
is pleased to announce that it has been granted a
European patent (EP4072552) by the European Patent
Office.
The patent relates to the Company's
lead product, ChemoSeed®, for chemotherapeutic drug implants and
more, particularly, to biodegradable chemotherapeutic drug implants
comprising irinotecan. ChemoSeed was invented by
Professor Chris McConville, CRISM's Chief Scientific
Officer.
The patent covers the manufacturing
processes for the preparation of these chemotherapeutic drug
implants and to their use in therapy, in particular in treating
brain tumours such as high grade glioma. The Company believes
that local delivery of irinotecan directly to the brain tumour
resection site could improve therapeutic outcomes by allowing for
the delivery of larger doses directly to the tumour site, while
reducing systemic concentrations and thus alleviating the
traditional side-effects.
The Company has patents submitted in
other key jurisdictions and will update the market as to their
progress accordingly.
Commenting on the patent grant, CRISM CEO Andrew Webb
said: "The granting of this patent by the European
patent office is a key milestone for CRISM and further validates
the novelty of ChemoSeed. Additionally, this provides CRISM IP
protection in one of our key markets whilst enhancing ChemoSeed's
appeal to potential commercial partners. The Board
believes that ChemoSeed could improve therapeutic outcomes for
brain tumour patients and we look forward to demonstrating this as
we prepare for a clinical trial in 2025."
-Ends-
Enquiries:
|
Company
|
Nomad and
Broker
|
Financial
PR
|
|
CRISM Therapeutics
Corporation
|
S.P. Angel Corporate Finance
LLP
|
Burson
Buchanan
|
|
Andrew
Webb, CEO
Chris
McConville, CSO
|
Richard
Morrison
Adam
Cowl
|
Mark
Court / Jamie Hooper
CRISM@buchanancomms.co.uk
|
|
via
Burson Buchanan
|
+44 (0)
20 3470 0470
|
+44 (0)
20 7466 5000
|
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has
developed an innovative drug delivery technology to improve the
clinical performance of cancer treatments for solid tumours through
the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can
be implanted directly into the tumour or the resection margin
following the removal of a tumour. This directs that therapeutic
concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of
treating high-grade glioma, ChemoSeeds can be implanted during
surgery thereby bypassing the blood brain barrier, which prevents
other treatments from being able to reach the tumour and be
effective.
CRISM plans to submit a clinical
trial application for ChemoSeed® in high-grade glioma. Based on preclinical data, the
Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved
ChemoSeed in a phase II platform clinical trial which is an
efficient and cost-effective clinical development
opportunity.
For more information please
visit: https://www.crismtherapeutics.com/
